ANNX
NASDAQ HealthcareAnnexon, Inc. - common stock
Biotechnology
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
�� 市场数据
| 价格 | $5.26 |
|---|---|
| 成交量 | 2,102,472 |
| 市值 | 861.81M |
| 贝塔系数 | 1.220 |
| RSI（14日） | 45.7 |
| 200日均线 | $4.56 |
| 50日均线 | $5.64 |
| 52周最高 | $7.18 |
| 52周最低 | $1.85 |
| Forward P/E | -5.70 |
| Price / Book | 4.18 |
🎯 投资策略评分
ANNX 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🚀 Moon Shot (75/100) — 此策略 高增长潜力（高贝塔 + 超卖）.
评分最低的策略： 💰 Dividend Daddy (21/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 ANNX in your text
粘贴任何文章、记录或帖子 — 工具将提取 ANNX 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-06-02.